Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Sutro Biopharma (NASDAQ: STRO) will host a virtual Research & Development Day on Wednesday, November 12, 2025 to present its platform innovation and next‑generation ADC pipeline.
The live webcast begins at 7:00 AM PT / 10:00 AM ET; investors can access the audio webcast at the company's investor relations events page and an archived replay will be posted after the event.
Sutro Biopharma (NASDAQ: STRO) terrà un giorno di Ricerca e Sviluppo virtuale il mercoledì 12 novembre 2025 per presentare l'innovazione della piattaforma e il portafoglio ADC di prossima generazione.
La trasmissione web in diretta inizia alle 7:00 AM PT / 10:00 AM ET; gli investitori possono accedere alla trasmissione audio sulla pagina degli eventi delle relazioni con gli investitori della società e una replica archiviata sarà pubblicata dopo l'evento.
Sutro Biopharma (NASDAQ: STRO) organizará un Día de Investigación y Desarrollo virtual el miércoles 12 de noviembre de 2025 para presentar su innovación de plataforma y la cartera de ADC de nueva generación.
La transmisión en vivo comienza a las 7:00 AM PT / 10:00 AM ET; los inversores pueden acceder a la transmisión de audio en la página de eventos de relaciones con inversores de la empresa y se publicará una reproducción archivada después del evento.
Sutro Biopharma (NASDAQ: STRO)은 연구 개발의 날이라는 가상 행사를 2025년 11월 12일 수요일에 개최하여 플랫폼 혁신과 차세대 ADC 파이프라인을 발표합니다.
라이브 웨비스트는 오전 7:00 PT / 오후 10:00 ET에 시작되며, 투자자들은 회사의 투자자 관계 이벤트 페이지에서 오디오 웨비스트에 접속할 수 있고 이벤트 후에 보관 재생이 게시됩니다.
Sutro Biopharma (NASDAQ: STRO) organisera une Journée Recherche et Développement virtuelle le mercredi 12 novembre 2025 pour présenter son innovation de plateforme et son pipeline ADC de nouvelle génération.
La diffusion en direct commence à 7h00 PT / 10h00 ET ; les investisseurs peuvent accéder à la diffusion audio sur la page des événements des relations investisseurs de l'entreprise et une rediffusion archivée sera publiée après l'événement.
Sutro Biopharma (NASDAQ: STRO) wird einen virtuellen Forschungs- und Entwicklungstag am Mittwoch, dem 12. November 2025 veranstalten, um Innovationen der Plattform und die Next-Generation-ADC-Pipeline vorzustellen.
Die Live-Übertragung beginnt um 7:00 Uhr PT / 10:00 Uhr ET; Investoren können auf die Audio-Webcast-Seite der Investor Relations-Events des Unternehmens zugreifen, und eine archivierte Wiedergabe wird nach der Veranstaltung veröffentlicht.
Sutro Biopharma (NASDAQ: STRO) ستعقد يوم البحث والتطوير افتراضي في يوم الأربعاء 12 نوفمبر 2025 لعرض ابتكار منصتها وخطة ADC من الجيل التالي.
تبدأ البث المباشر في الساعة 7:00 صباحًا بتوقيت المحيط الهادئ / 10:00 صباحًا بتوقيت الشرقية؛ يمكن للمستثمرين الوصول إلى البث الصوتي على صفحة فعاليات العلاقات مع المستثمرين بالشركة وسيتم نشر إعادة تشغيل أرشيفية بعد الحدث.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline.
The live webcast will be held on Wednesday, November 12, 2025, starting at 7:00AM PT / 10:00AM ET.
Webcast Information:
To access the live audio webcast, please go to https://ir.sutrobio.com/news-events/ir-calendar. An archived replay of the webcast will be available on the Company’s website following the event.
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com